Building upon a series of successful preclinical studies, researchers at MassBiologics of the University of Massachusetts Medical School (UMMS) today announced the beginning of a Phase 1 clinical trial, testing the safety and activity of a human monoclonal antibody they developed that can neutralize the Hepatitis C virus.

Greystone Associates Report Analyzes Clinical, Regulatory and Therapeutic Factors Driving Growth of Immune Factor Drugs

U.S. Military HIV Research Program (USMHRP) researcher Victoria R. Polonis, Ph.D., and colleagues released findings on a study of cross-clade neutralization patterns among HIV-1 strains from six major clades in the 5 Jun 2008 issue of Virology.

IRI Separation Technologies (TSX.V:IRI) is the manufacturer of a remarkable new dietary supplement that enhances the human body’s natural immune system through direct supplementation of actual antibodies . The product will be available in the United States and Canada under the brand name “Muno Boost” and will be available as an over-the-counter dietary supplement in pharmacies and through direct marketing.

Scientists have developed a new, faster way to create human monoclonal antibodies against infectious disease by tapping the immune system at the peak of its powers.

Researchers devise new method of creating human antibodies to flu, other illnesses.

Now, a group of Scripps Research scientists have shown that EP2-19G2, one of a panel of fluorescent monoclonal antibodies that were first reported in 2000, produces its distinctive bright blue glow through a rare and highly complex recombination of electrical charge.

The mothers of some autistic children may have made antibodies against their fetuses’ brain tissue during pregnancy that crossed the placenta and caused changes that led to autism, suggests research led by Johns Hopkins Children’s Center investigators and published in the February issue of the Journal of Neuroimmunology.

Two novel proteins studied by a University at Buffalo professor of microbiology and immunology appear to have the potential to enhance the production of antibodies against a multitude of infectious agents.

Researchers at Washington University School of Medicine in St. Louis have shown that a controversial phenomenon known as antibody-dependent enhancement (ADE) of infection is suppressed by C1q, a blood-borne immune system compound.

Researchers from the University of Pittsburgh School of Medicine report a significant new advance in the search for an effective treatment for human liver cancer in the July issue of Molecular Cancer Therapeutics. Using a newly available monoclonal antibody, they demonstrated significant reductions in tumor cell proliferation and survival in human and mouse hepatocellular cancer (HCC) cell lines.